|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0032854,
umls-concept:C0034804,
umls-concept:C0278493,
umls-concept:C0279025,
umls-concept:C0332281,
umls-concept:C0871261,
umls-concept:C1517945,
umls-concept:C1561558,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1996-10-30
|
|
pubmed:abstractText |
Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy. We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2584-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8823339-Adult,
pubmed-meshheading:8823339-Aged,
pubmed-meshheading:8823339-Antineoplastic Agents, Hormonal,
pubmed-meshheading:8823339-Breast Neoplasms,
pubmed-meshheading:8823339-Female,
pubmed-meshheading:8823339-Humans,
pubmed-meshheading:8823339-Immunohistochemistry,
pubmed-meshheading:8823339-In Situ Hybridization,
pubmed-meshheading:8823339-Lymphatic Metastasis,
pubmed-meshheading:8823339-Middle Aged,
pubmed-meshheading:8823339-Neoplasm Metastasis,
pubmed-meshheading:8823339-Neoplasm Recurrence, Local,
pubmed-meshheading:8823339-Predictive Value of Tests,
pubmed-meshheading:8823339-Prognosis,
pubmed-meshheading:8823339-Receptors, Estrogen,
pubmed-meshheading:8823339-Receptors, Progesterone,
pubmed-meshheading:8823339-Tamoxifen
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
|
|
pubmed:affiliation |
Department of Pathology, Tampere University Hospital, University of Tampere, Finland. bltuku@uta.ft
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
